



SINGAPORE



# Cennerv Pharma

## Company Description

Cennerv Pharma is a drug discovery and development company focused on bringing therapeutic small molecules for mental illnesses to market. We target diseases like depression, insomnia, dementia, attention-deficit hyperactivity disorder and Alzheimer's diseases. The many advances of medical science have impacted very positively on the life span of the human being. However, with this extension of longevity, come the problems of growing old. The world is facing an increasing global population and, in particular, a rapidly ageing population. Herein lies the tremendous opportunity for our products improving the quality of life years for humans and impacting on the dignity of those suffering from mental disorders.

## Pipeline and Development


Cennerv's portfolio comprises two clinical stage and three preclinical stage compounds. These compounds have shown efficacy either in humans or in predictive animal models of disease. CB2810 is a repurposed compound that has shown efficacy in a polysomnography study in animals and it is being reformulated as a sublingual compound targeting insomnia in elderly. CB2202 is a reversible, selective monoamine oxidase A inhibitor that has shown efficacy in treatment resistant depression. CB2233 and CB8411 has shown efficacy in non-human primate models of memory, while CB0306 has shown efficacy in proprietary animal model for psychosis.

Product	Pre Clinical	Clinical Development			Disease Indication
		PHASE 1	PHASE 2	PHASE 3	
CB2810					Insomnia
CB2202					Major Depressive Disorder
CB2233					Dementia/ Alzheimer's
CB8411					Dementia/ ADHD
CB0306					Autism

## Investors and Partners

- Equity Investment from strategic or financial investors.
- Partners in China, Europe, US and Japan

For more information, please visit [www.ausbiotechinvestment.com.au](http://www.ausbiotechinvestment.com.au)

 Follow us for the latest event update [#AsiaBioInv](https://twitter.com/AsiaBioInv)